ERBB2 and breast cancer: The authors found significantly higher SUVmax values in the total population of TNBC patients and across subgroups by tumor size, grade, and stage, compared to the ER-positive/PR-positive/HER2-negative breast cancer group, suggesting increased tumor glycolysis may contribute to the aggressiveness of TNBC (70).